Arca
Skip to content
Tools
Tools

ALK: ALK tyrosine kinase receptor

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Neuronal receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems and plays an important role in the genesis and differentiation of the nervous system.

  • Drugs that act on it: 11
  • Approved: 7
  • In phases 1 to 3: 4
  • Sponsors: 9

Who Is On It, and How Far Along

Every drug ChEMBL records acting on ALK, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule
  • Other

Approved7

  • Alectinib
  • Lorlatinib
  • Crizotinib
  • Entrectinib
  • Ensartinib
  • Brigatinib
  • Ceritinib

Phase 30

    Phase 20

      Phase 14

      • Conteltinib
      • ASP-3026
      • CEP-37440
      • PLB1003

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      • Beijing Pearl Biotechnology Limited Liability Company19%
      • Centaurus Biopharma Co., Ltd.19%

      Modalities

      Drugs on this target by ChEMBL molecule type.

      • Small molecule1091%
      • Other19%

      The Landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: ALK tyrosine kinase receptor inhibitor.
      AlectinibApprovedRocheSmall moleculeInhibitor—44—
      LorlatinibApprovedPfizerSmall moleculeInhibitor—42—
      CrizotinibApprovedPfizerSmall moleculeInhibitor—39—
      EntrectinibApprovedRocheSmall moleculeInhibitor—26—
      EnsartinibApprovedXcoverySmall moleculeInhibitor—22—
      BrigatinibApprovedTakeda Pharmaceuticals USASmall moleculeInhibitor—17—
      CeritinibApprovedNovartis PharmaceuticalsSmall moleculeInhibitor—11—
      ConteltinibPhase 1Centaurus Biopharma Co., Ltd.Small moleculeInhibitor—1—
      ASP-3026Phase 1Astellas PharmaSmall moleculeInhibitor—0—
      CEP-37440Phase 1Teva Pharmaceutical IndustriesSmall moleculeInhibitor—0—
      PLB1003Phase 1Beijing Pearl Biotechnology Limited Liability CompanyOtherInhibitor—0—

      Open Trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 46 in all, from ClinicalTrials.gov.
      Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLCLorlatinibPhase 1Not yet recruitingDana-Farber Cancer Institute2026-11-16
      Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric GliomaAlectinib, EntrectinibPhase 2Not yet recruitingSt. Jude Children's Research Hospital2026-11-04
      Ceritinib Treatment for Recurrent MeningiomasCeritinibPhase 2Not yet recruitingKevin Petrecca2026-10-23
      Master Protocol for Basket Clinical Trials of Targeted Therapies Based on Proteome and Whole Exome Sequencing Screening in Patients With Advanced Solid TumorsCrizotinibNot applicableActive, not recruitingNational Cancer Center, Korea2026-10-23
      Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver MutationsAlectinib, EntrectinibPhase 2Not yet recruitingShanghai Zhongshan Hospital2026-09-21
      TailorDose Lung: Decentralized TDM of Taxanes and ALK Inhibitors Using Capillary Self-SamplingAlectinib, LorlatinibNot applicableNot yet recruitingKarolinska Institutet2026-09-16
      A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung CancerCrizotinibPhase 3Not yet recruitingGuangzhou JOYO Pharma Co., Ltd2026-09-11
      Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal MelanomaCrizotinibPhase 3RecruitingIDEAYA Biosciences2026-09-04
      Molecularly Tailored Therapy in Advanced Pancreatic CancerCrizotinibPhase 2Not yet recruitingHerlev Hospital2026-09-03
      Study of NXP900 With Lorlatinib in ALK+ Lung CancerLorlatinibPhase 1RecruitingNuvectis Pharma, Inc.2026-08-25
      Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving LorlatinibLorlatinibPhase 1RecruitingUniversity of Chicago2026-08-24
      A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung CancerAlectinib, BrigatinibPhase 2Not yet recruitingFirst Affiliated Hospital of Fujian Medical University2026-08-18
      Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLCLorlatinibPhase 2Not yet recruitingGuangdong Association of Clinical Trials2026-08-06
      Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLCLorlatinib—Not yet recruitingSun Yat-sen University2026-06-29
      Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / MixedLorlatinibPhase 4Not yet recruitingHunan Cancer Hospital2026-06-29
      Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLCEnsartinib, LorlatinibPhase 4Not yet recruitingQiming Wang2026-06-26
      OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic TherapyAlectinib, BrigatinibPhase 1RecruitingM.D. Anderson Cancer Center2026-06-18
      Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and ChemotherapyAlectinibPhase 2Not yet recruitingWen-zhao ZHONG2026-05-07
      Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)Alectinib, CrizotinibPhase 1 / Phase 2Not yet recruitingChina Medical University Hospital2026-05-01
      A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver FunctionCrizotinibPhase 1Not yet recruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.2026-04-20
      Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.EnsartinibPhase 1 / Phase 2RecruitingBetta Pharmaceuticals Co., Ltd.2026-03-04
      Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)EnsartinibPhase 1 / Phase 2RecruitingTang-Du Hospital2026-01-21
      Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLCEnsartinibPhase 2Not yet recruitingShanghai Pulmonary Hospital, Shanghai, China2025-11-19
      Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell CarcinomaAlectinib, Crizotinib—RecruitingFirst People's Hospital of Hangzhou2025-10-03
      Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib ProgressionEntrectinib—Not yet recruitingInnovent Biologics (Suzhou) Co. Ltd.2025-09-30
      Study on the Mechanism of Acquired Resistance of EntrectinibEntrectinib—RecruitingFudan University2025-09-30
      Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C MutationConteltinibPhase 1 / Phase 2Not yet recruitingShouyao Holdings (Beijing) Co. LTD2025-05-14
      Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver MutationsEnsartinibPhase 3Not yet recruitingThe First Affiliated Hospital of Guangzhou Medical University2025-05-02
      Using Tumor Models to Determine TreatmentsBrigatinib, CeritinibPhase 2RecruitingUniversity Health Network, Toronto2025-02-06
      Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma :A Multicenter, Real-World Clinical StudyEnsartinibPhase 4Not yet recruitingFujian Medical University Union Hospital2025-01-21
      Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRDEnsartinibPhase 2Not yet recruitingPeking University Cancer Hospital & Institute2025-01-17
      Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung CancerEnsartinibPhase 2Not yet recruitingWest China Hospital2025-01-16
      Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLCCrizotinib, Entrectinib—Not yet recruitingNational Cancer Center, China2024-11-19
      Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSEntrectinibPhase 2Not yet recruitingPeking University Shenzhen Hospital2024-11-18
      Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by BrigatinibBrigatinibPhase 2RecruitingGroupe Francais De Pneumo-Cancerologie2024-10-01
      Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS TumorsEntrectinibPhase 2RecruitingSt. Jude Children's Research Hospital2024-07-30
      Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerEntrectinibPhase 2RecruitingWest China Hospital2024-07-01
      A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETYBrigatinib—Active, not recruitingTakeda2023-02-21
      A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)Brigatinib—Active, not recruitingTakeda2023-02-10
      Antineoplastic Drugs in Elderly PatientsCeritinib—RecruitingShandong University2022-07-20
      A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)Brigatinib, CeritinibPhase 1 / Phase 2RecruitingNuvalent Inc.2022-05-20
      Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)BrigatinibPhase 2Active, not recruitingIntergroupe Francophone de Cancerologie Thoracique2022-01-20
      Improving Public Cancer Care by Implementing Precision Medicine in NorwayCeritinibPhase 2RecruitingOslo University Hospital2021-03-26
      Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationCeritinibPhase 2RecruitingHunan Province Tumor Hospital2020-03-26
      Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLCCeritinibPhase 1Active, not recruitingH. Lee Moffitt Cancer Center and Research Institute2018-08-02
      Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored StudyCeritinibPhase 4Active, not recruitingNovartis Pharmaceuticals2015-10-23

      Diseases Most Associated With It

      Open Targets association score, 0 to 1; all associations
      Neuroblastoma, susceptibility to, 3
      0.76
      Non-small cell lung carcinoma
      0.76
      Cancer
      0.76
      Neoplasm
      0.67
      Lung adenocarcinoma
      0.49
      Squamous cell lung carcinoma
      0.47
      Inflammatory myofibroblastic tumor
      0.43
      Hereditary neoplastic syndrome
      0.42

      Genes and Related Targets

      Complexes and families that share a gene with this target
      Genes
      ALK

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL4247, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q9UM73, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.